BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 10632331)

  • 1. Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow.
    Braun S; Hepp F; Kentenich CR; Janni W; Pantel K; Riethmüller G; Willgeroth F; Sommer HL
    Clin Cancer Res; 1999 Dec; 5(12):3999-4004. PubMed ID: 10632331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential immunochemotherapy and edrecolomab in the adjuvant therapy of breast cancer: reduction of 17-1A-positive disseminated tumour cells.
    Kirchner EM; Gerhards R; Voigtmann R
    Ann Oncol; 2002 Jul; 13(7):1044-8. PubMed ID: 12176782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-antigen heterogeneity of disseminated breast cancer cells: implications for immunotherapy of minimal residual disease.
    Braun S; Hepp F; Sommer HL; Pantel K
    Int J Cancer; 1999 Feb; 84(1):1-5. PubMed ID: 9988223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy.
    Thurm H; Ebel S; Kentenich C; Hemsen A; Riethdorf S; Coith C; Wallwiener D; Braun S; Oberhoff C; Jänicke F; Pantel K
    Clin Cancer Res; 2003 Jul; 9(7):2598-604. PubMed ID: 12855636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of cytokeratin 19 fragment (CYFRA 21-1) and cytokeratin-positive cells in bone marrow samples of breast cancer patients.
    Pierga JY; Deneux L; Bonneton C; Vincent-Salomon A; Nos C; Anract P; Magdelénat H; Pouillart P; Thiery JP
    Int J Biol Markers; 2004; 19(1):23-31. PubMed ID: 15077923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EpCAM: A new therapeutic target for an old cancer antigen.
    Armstrong A; Eck SL
    Cancer Biol Ther; 2003; 2(4):320-6. PubMed ID: 14508099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients.
    Deng G; Herrler M; Burgess D; Manna E; Krag D; Burke JF
    Breast Cancer Res; 2008; 10(4):R69. PubMed ID: 18687126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer.
    Schneck H; Gierke B; Uppenkamp F; Behrens B; Niederacher D; Stoecklein NH; Templin MF; Pawlak M; Fehm T; Neubauer H;
    PLoS One; 2015; 10(12):e0144535. PubMed ID: 26695635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients.
    Lustberg MB; Balasubramanian P; Miller B; Garcia-Villa A; Deighan C; Wu Y; Carothers S; Berger M; Ramaswamy B; Macrae ER; Wesolowski R; Layman RM; Mrozek E; Pan X; Summers TA; Shapiro CL; Chalmers JJ
    Breast Cancer Res; 2014 Mar; 16(2):R23. PubMed ID: 24602188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow.
    Pantel K; Schlimok G; Angstwurm M; Weckermann D; Schmaus W; Gath H; Passlick B; Izbicki JR; Riethmüller G
    J Hematother; 1994; 3(3):165-73. PubMed ID: 7530132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of metastatic carcinoma cells in bone marrow by intravenously administered monoclonal antibody: towards a novel surrogate test to monitor adjuvant therapies of solid tumours.
    Schlimok G; Pantel K; Loibner H; Fackler-Schwalbe I; Riethmüller G
    Eur J Cancer; 1995 Oct; 31A(11):1799-803. PubMed ID: 8541104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug evaluation: IGN-101--an anti-EpCAM murine antibody vaccine for cancer.
    Kirman I
    Curr Opin Mol Ther; 2006 Aug; 8(4):358-65. PubMed ID: 16955700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test.
    Adams DL; Stefansson S; Haudenschild C; Martin SS; Charpentier M; Chumsri S; Cristofanilli M; Tang CM; Alpaugh RK
    Cytometry A; 2015 Feb; 87(2):137-44. PubMed ID: 25515318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells.
    Fehm T; Hoffmann O; Aktas B; Becker S; Solomayer EF; Wallwiener D; Kimmig R; Kasimir-Bauer S
    Breast Cancer Res; 2009; 11(4):R59. PubMed ID: 19664291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients.
    Braun S; Kentenich C; Janni W; Hepp F; de Waal J; Willgeroth F; Sommer H; Pantel K
    J Clin Oncol; 2000 Jan; 18(1):80-6. PubMed ID: 10623696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rare expression of target antigens for immunotherapy on disseminated tumor cells in breast cancer patients without overt metastases.
    Kasimir-Bauer S; Otterbach F; Oberhoff C; Schmid KW; Kimmig R; Seeber S
    Int J Mol Med; 2003 Dec; 12(6):969-75. PubMed ID: 14612976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.
    Moldenhauer G; Salnikov AV; Lüttgau S; Herr I; Anderl J; Faulstich H
    J Natl Cancer Inst; 2012 Apr; 104(8):622-34. PubMed ID: 22457476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enrichment methods to detect bone marrow micrometastases in breast carcinoma patients: clinical relevance.
    Choesmel V; Pierga JY; Nos C; Vincent-Salomon A; Sigal-Zafrani B; Thiery JP; Blin N
    Breast Cancer Res; 2004; 6(5):R556-70. PubMed ID: 15318937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection and clinical relevance of early disseminated breast cancer cells depend on their cytokeratin expression pattern.
    Effenberger KE; Borgen E; Eulenburg CZ; Bartkowiak K; Grosser A; Synnestvedt M; Kaaresen R; Brandt B; Nesland JM; Pantel K; Naume B
    Breast Cancer Res Treat; 2011 Feb; 125(3):729-38. PubMed ID: 20449649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients.
    Watson MA; Ylagan LR; Trinkaus KM; Gillanders WE; Naughton MJ; Weilbaecher KN; Fleming TP; Aft RL
    Clin Cancer Res; 2007 Sep; 13(17):5001-9. PubMed ID: 17785550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.